Functional significance of UDP-Glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites

Cancer Research

Volumn 69, Issue 5, 2009, Pages 1892-1900

  Blevins Primeau, Andrea S ^a,b   Sun, Dongxiao ^a,b   Chen, Gang ^a,b   Sharma, Arun K ^a,b   Gallagher, Carla J ^a,b   Amin, Shantu ^a,b   Lazaru, Philip ^a,b  

^a PENN STATE CANCER INSTITUTE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ENDOXIFEN; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 2B7; TAMOXIFEN; UNCLASSIFIED DRUG; 4 HYDROXYNORTAMOXIFEN; 4-HYDROXY-N-DESMETHYLTAMOXIFEN; 4-HYDROXYTAMOXIFEN; ANTIESTROGEN; BILIRUBIN GLUCURONOSIDE GLUCURONOSYLTRANSFERASE; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A10; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A10; CYTOCHROME P450 2D6; DRUG DERIVATIVE; UDP GLUCURONOSYLTRANSFERASE, UGT1A8; UDP-GLUCURONOSYLTRANSFERASE, UGT1A8; UGT2B7 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CELL LINE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG METABOLISM; EMBRYO; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GLUCURONIDATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INDIVIDUALITY; LIVER MICROSOME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TRANS ISOMER; TREATMENT RESPONSE; WILD TYPE; GENETICS; METABOLISM; PHYSIOLOGY;

CELL LINE; CYTOCHROME P-450 CYP2D6; ESTROGEN ANTAGONISTS; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; TAMOXIFEN;

EID: 62449183686     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3708     Document Type: Article

References (56)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen, for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-I. Study. J Natl Cancer Inst 1998;90:1371-88.
2. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-1618
3. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
4. Howell A, Howell SJ, Evans DG. New approaches to the endocrine prevention and treatment of breast cancer. Cancer Chemother Pharmacol 2003;52(Suppl l):S39-44.
5. Ghosh SS, Sappal BS, Kalpana GV, Lee SW, Chowdhury JR, Chowdhury NR. Homodimerization of human bilirubin-uridine-diphosphoglucuronate glucuronosyl-transferase-1. (UGTIAl.) and its functional implications. J Biol Chem 2001;276:42108-42115.
6. Nechushtan H, Peretz T. [Tamoxifen, and breast cancer], Harefuah 2002;141:718-20, 61, 60.
7. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 1991;303:435-437.
8. Rutqvist LE, Mattsson A Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993;85:1398-1406.
9. van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-452.
10. Rutqvist LE, Johansson H, Slgnomklao T, Johansson U, Fomander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995;87:645-651.
11. Meier CR, Jick H. Tamoxifen and risk, of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998:45: 608-612.
12. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collab-orative Group. Lancet 1998;351:1451-1467.
13. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxlfen-treated breast cancer patients: findings from, the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-1.4. J Natl Cancer Inst 1994;86:527-537.
14. Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl. Cancer Inst. 1999;91:1654-1662.
15. Bergman L, Beelen ML, Gallee MP, Holleina H, Benraadt J, van. Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen, for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assess-ment of Liver and Endometrial cancer Risk following Tamoxifen Lancet 2000;356:881-887.
16. Jordan. VC, Collins MM, Rowsby L1 Prestwlch G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 1977;75: 305-16.
17. Furr BJ Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther. 1984 25:127-205.
18. Katzenellenbogen BS Norman MJ Eckert RL, Peltz SW Mangel WF. Bioactivities, estrogen receptor inter-actions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 1984 44:112-119.
19. Borges S, Desta Z, LI L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metab-olism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006:80:61-74.
20. Johnson MD, Zuo H, Lee KH, et al. Pharmacological characterization, of 4-hydroxy-/V-desmethyi. tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004:85:151-9.
21. Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-JV- desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Phannacol 2005; 55:471-8
22. Buckley MM, Goa KL. Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 1989;37:451-459.
23. Chu W, Fyles A, Sellers EM, et al. Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis 2007; 28:2139-42.
24. Robertson DW, Katzenellenbogen JA, Long DJ, Rorke EA, Katzenellenbogen BS. Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and tram isomers of tamoxifen. J Steroid Biochem 1982;16:1-13.
25. Malet C, Spritzer P, Cumins C, Guillaumin D, Mauvais-Jarvis P, Kuttenn F. Effect of 4-hydroxytamox-ifen isomers on growth and ultrastructural aspects of normal human, breast epithelial (HBE) cells in culture. J Steroid Biochem MoI Biol 2002:82:289-96
26. Zheng Y, Sun D, Sharma AK, Chen G, Amin S, Lazarus P. Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation. Drug Metab Dispos 2007;35:1942-1948.
27. Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM. Distribution of 4-hydroxy-Ar-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 1989;49:2175-83.
28. Lien EA Solheim E, Kvinnsland S, Ueland PM. identification of 4-hydroxy-W-desmethyitamoxlfen as a metabolite of tamoxifen in human, bile. Cancer Res 1988; 48:2304-08.
29. Nowell SA, Ahn J, Rae JM, et al. Association, of genetic variation in tamoxifen-metabolizing enzymes with overall survival, and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005; 91:249-258.
30. Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, Lazarus P. Characterization of tamoxifen and 4-hydroxytamoxlfen glucuronidation by human UGT1.A4 variants. Breast Cancer Res 2006;8:R50.
31. Sun D, Sharma AK, Dellinger RW et al. Glucuroni-dation of active tamoxifen, metabolites by the human UDP-glucuronosyltransferases (UGTs). Drug Metab Dis-pos 2007;35:2006-14.
32. Coffman BL, King CD, Rios GR, Tephly TR The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998;26:73-77
33. Dellinger RW, Fang JL, Chen G, Weinberg R, Lazarus P. Importance of UDP-glucuronosyltransferase IAIO (UGTlAlO) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGTlA10139Lys isoform. Drug Metab Dispos 2006;34 943-949.
34. Wiener D, Fang JL, Dossett N, Lazarus P. Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-l.-(3-pyrldyl)- l.-butanone glucuro-nidation phenotype in human liver microsomes. Cancer Res 2004:64:1190-6.
35. Lazarus P, Zheng Y, Aaron Runkle E, Muscat JE, Wiener D. Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion, and NNAL glucuronidation activities in human liver microsomes. Pharmacogenet Genomics 2005;15:769-778
36. Huang CK, Dulau A, Su-Rick CJ, Pan Q. Validation of rapid polymerase chain reaction-based, detection of all length polymorphisms in the UGT IAl. gene promoter. Diagn MoI Pathol 2007;16:50-3.
37. Elahi A, Bendaly J, Zheng Z, et al. Detection of UGTIAlO polymorphisms and their association with orolaryngeal carcinoma risk. Cancer 2003;98:872-880.
38. Huang YH, Galljatovic A, Nguyen N, et al. Identifica-tion and functional characterization of UDP-glucurono-syltransferases UGT1A8*, UGT1A8*2 and UGT1A8*3. Pharmacogenetics 2002;12:287-97.
39. Nakamura A, Nakajlma M1 Yamanaka H1 Fujlwara R1 Yokoi T. Expression of UGTlA and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 2008;36:1.46.1-4.
40. Ren Q1 Murphy SE, Zheng Z, Lazarus P. 0-Glucuronidation of the lung carcinogen. 4-(methyinitro-8amino)-l-(3-pyridyl)-l.-butanal (NNAI.) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos 2000;28:1352-1360.
41. Strassburg CP, Strasshurg A, Nguyen N, Li Q, Manns MP, Tukey RH. Regulation and function, of family 1 and family 2 UDP-glucuronosyltransferase genes (UGTlA, UGT2B) in human oesophagus. Biochem J 1999:338: 489-498.
42. Turgeon D, Carrier JS, Levesque E, Hum DW, Belanger A. Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 2001;142:778-787.
43. Zheng Z, Fang JL, Lazarus P. Glucuronidation: an important mechanism, for detoxification, of benzo[ajpy-yrene metabolites in aerodigestive tract tissues. Drug Metab Dispos 2002;30:397-403.
44. Innocent! F, Liu W, Fackenthal D, et al. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltrans- ferase 2B7 gene. Pharmacogenet Genomics 2008:18: 683-697
45. Fang JL, Lazarus P. Correlation between, the UDP-glucuronosyltransferase (UGTlAl) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(«)pyrene-7, 8-dihydrodiol(-) in liver microsomes from subjects with the UGT1A.1*28 variant. Cancer Epidemiol Biomarkers Prev 200413: 1.02-9.
46. Hsieh TY, Shiu TY, Huang SM, et al. Molecular pathogenesis of Gilbert's syndrome: decreased TATA-binding protein, binding affinity of UGTlAl. gene promoter. Pharmacogenet Genomics 2007;17:229-236.
47. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995;333:1171-1175.
48. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation, in bilirubin UPD-glucuronosyltrans-ferase gene promoter and Gilbert's syndrome. Lancet 1996;347:578-81.
49. Iyer L, King CD, Whitlngton PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform IAl in the glucuronidation of Its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998;101:847-854.
50. Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in. human liver tissue with UGTlAI promoter polymorphism. Clin Pharmacol Ther 1999:65:576-582.
51. Ogura K, Ishikawa Y, Kaku T1 et al. Quaternary ammonium-linked glucuronidation of trans-4-hydroxy-tamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1.A.4 Biochem Pharmacol 2006;71:1358-1369.
52. Bernard O, Tojcic J, Journault K, Perusse L, Guillem-ette C. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of myco-phenolic acid. Drug Metab Dispos 2006;34:1539-1545.
53. Lehmann L1 Wagner J. Gene expression, of I7ß-estradiol-metabolizing isozymes: comparison of normal human mammary gland to normal human, liver and to cultured human breast adenocarcinoma cells. Adv Exp Med Biol 2008;617:617-624.
54. Thibaudeau J1 Lepine J1 Tojcic J, et al. Characteriza-tion of common UCTIAS, UGT.1A9, and UGT2B7 variants with different capacities to inactivate muta-genic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res 2006;66:125-133
55. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen, biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-18
56. Goetz MP, Knox SK, Suman VJ, et al The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113-121.